Home > Dermatology > EADV 2022 > Biologic therapy in HS patients: unmet needs due to high rate of non-responders

Biologic therapy in HS patients: unmet needs due to high rate of non-responders

Presented By
Dr Hayley Wallinger, Adelphi Real World, United Kingdom
Conference
EADV 2022
Biologics are a recently approved treatment modality for hidradenitis suppurativa (HS). However, the considerable proportion of patients who do not respond efficiently experience a significant burden of disease, poor disease control, and a higher impact on quality-of-life, underscoring a high degree of unmet needs that demand novel treatments.  HS is a chronic inflammatory skin disease characterised by recurrent outbreaks of skin lesions that can lead to permanent scarring in the absence of prompt treatment. The recent approval of adalimumab has introduced biologic therapy, yet its effectiveness needs further evaluation To address this issue, Dr Hayley Wallinger (Adelphi Real World, United Kingdom) and her team examined the real-world data drawn from the Adelphi HS Disease Specific Programme, a point-in-time survey of physicians and their consulting HS patients conducted in the USA, France, Germany, Italy, Spain, and the United Kingdom between Novem...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on